Professor Michael McClung is the founding director of the Oregon Osteoporosis Center. He is a graduate of the University of Texas Southwestern Medical School in Dallas and completed a fellowship in Endocrinology at the National Institute of Health in Bethesda, Maryland. For many years, he was on the faculty at the Oregon Health Sciences University and in the Department of Medical Education at Providence Portland Medical Center where he was actively involved in the training of young physicians.
At the Oregon Osteoporosis Center, Dr. McClung has had an active clinical practice, taken part in multiple educational initiatives and has been the principal investigator in many clinical trials evaluating the effects of therapeutic agents for osteoporosis and utility of tests for diagnosis and monitoring that disease. These activities have resulted in more than 250 scientific and clinical publications. He is frequently invited to speak at national and international society meetings and is the recipient of several teaching and service awards from those societies, including, in 2015, the President’s Award from the International Osteoporosis Foundation, the Dr. John P. Bilezikian Global Leadership Award of the International Society for Clinical Densitometry and the Leon Speroff Award for Excellence in Education from the North American Menopause Society. Dr. McClung serves as the Associate Clinical Editor of BoneKey and is on the editorial board of several other journals including Osteoporosis International. He has been an active member of the IOF Council of Scientific Advisors since 1999. Dr. McClung served on the WHO Fracture Risk Assessment Task Force that led to the implementation of the FRAX fracture risk assessment tool, and he has been involved in the development of clinical guidelines for several national osteoporosis societies.
Osteoporosis Therapy In Elderly Patients
The incidence of fragility fracture increases with advancing age, and osteoporosis (impaired bone strength) and falls are the most important risk factors for these fractures. Because the contribution of falls increases with aging, questions arose about the efficacy (as well as the safety) of osteoporosis medication in the very elderly. Data from clinical trials documents that the absolute risk of fracture in greater in older subsets of elderly patients, and while the relative reduction in fracture risk may not be as great in older compared to younger patients, the absolute reduction in fracture risk, and the benefit:risk ratio of therapy is greater in elderly patients. Using these data, the role of pharmacological therapies for osteoporosis in elderly adults at risk of fracture will be discussed.
Call for Abstracts open: 25th October 2016
Registration Opens: 18th November 2016
Call for Abstracts Closes: 24th February 2017
Notification of Abstracts: 20th March 2017
Close of Early Registration: 31st March 2017
Conference: 10th May 2017
Australian and New Zealand Society for Geriatric Medicine (ANZSGM)
145 Macquarie Street
Sydney NSW 2000, Australia
Tel: +61 2 9256 5460
Fax: +61 2 9241 3458